Small Cell Lung Cancer News and Research RSS Feed - Small Cell Lung Cancer News and Research

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.
Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Helsinn, a Swiss Group focused on building quality cancer care, and Mundipharma, today announce that they have entered into a distribution and license agreement for the exclusive rights to anamorelin in China, Hong Kong and Macao. [More]
Agena Bioscience releases LungFUSION Panel to identify gene fusions in NSCLC tumors

Agena Bioscience releases LungFUSION Panel to identify gene fusions in NSCLC tumors

Agena Bioscience today released the LungFUSION Panel for rapid and sensitive identification of oncogenic ALK, RET, and ROS1 gene fusions in non-small cell lung cancer tumors. [More]
TPU's submission of Docetaxel Injection Concentrate, Non-Alcohol Formula NDA acknowledged by FDA

TPU's submission of Docetaxel Injection Concentrate, Non-Alcohol Formula NDA acknowledged by FDA

Teikoku Pharma USA announced today that it has submitted a 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration for Docetaxel Injection Concentrate, Non-Alcohol Formula on February 26, 2015 and received an acknowledgment of the receipt from FDA. [More]
Eli Lilly, Innovent Biologics announce biotech drug development collaborations in China

Eli Lilly, Innovent Biologics announce biotech drug development collaborations in China

Eli Lilly and Company and Innovent Biologics, Inc. today announced one of the largest biotech drug development collaborations in China to date between a multi-national and domestic company. [More]
Physicians, researchers to discuss advances in cancer immunotherapies at UChicago symposium

Physicians, researchers to discuss advances in cancer immunotherapies at UChicago symposium

The Ben May Department for Cancer Research at the University of Chicago will hold a day-long symposium on cancer immunotherapy for physicians and researchers. [More]
Patients who receive definitive CCRT treatment for stage III NSCLC have longer overall survival

Patients who receive definitive CCRT treatment for stage III NSCLC have longer overall survival

Patients treated with definitive concurrent chemotherapy and radiation therapy (CCRT) for stage III non-small cell lung cancer (NSCLC) have longer overall survival when treated by highly experienced facilities, whether or not they are academic or community cancer centers. [More]
Advanced Cell Diagnostics' RNAscope technology supports biomarker-selected phase 2 clinical trial of Merrimack Pharmaceuticals' MM-121

Advanced Cell Diagnostics' RNAscope technology supports biomarker-selected phase 2 clinical trial of Merrimack Pharmaceuticals' MM-121

Advanced Cell Diagnostics, Inc. (ACD) announced today that Merrimack Pharmaceuticals, Inc. is using ACD's RNAscope technology to select patients for its Phase 2 clinical trial of its product candidate MM-121. [More]
CRISPR-Cas9 gene-editing technology targets every gene in the genome in animal cancer model

CRISPR-Cas9 gene-editing technology targets every gene in the genome in animal cancer model

For the first time, CRISPR-Cas9 gene-editing technology has been employed in a whole organism model to systematically target every gene in the genome. [More]
New online tool helps educate practicing oncologists with therapeutic decision-making for NSCLC

New online tool helps educate practicing oncologists with therapeutic decision-making for NSCLC

A new interactive online tool helps educate practicing oncologists worldwide with therapeutic decision-making for advanced non-small cell lung cancer (NSCLC) based on a patient's molecular and clinical characteristics by providing feedback from an expert panel. [More]
Facts about precision medicine

Facts about precision medicine

President Barack Obama is requesting an increase of $215 million in the 2016 federal budget to launch the Precision Medicine Initiative. This boost in funding for research will give genetic causes of cancer a national focus specifically around precision or "personalized" treatments for cancer in the future. [More]
CTCA presents research on new cancer nutrition therapies at A.S.P.E.N. Clinical Nutrition Week

CTCA presents research on new cancer nutrition therapies at A.S.P.E.N. Clinical Nutrition Week

Several Cancer Treatment Centers of America clinicians presented research from studies evaluating new cancer nutrition techniques and therapies at the American Society for Parenteral and Enteral Nutrition Clinical Nutrition Week held in Long Beach, Calif., February 14-17, 2015. CTCA clinicians led a plenary session and an oral abstract presentation, and presented eight posters to Clinical Nutrition Week attendees. [More]
Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). [More]
Franziska Michor named winner of Creative Promise Prize in Biomedical Science

Franziska Michor named winner of Creative Promise Prize in Biomedical Science

Franziska Michor was picked as the winner of a Creative Promise Prize in Biomedical Science for her research that fuses evolutionary biology, mathematics, and clinical research toward a better understanding of cancer genesis and treatments. [More]
Discovery leads to new understanding of cancer metastasis

Discovery leads to new understanding of cancer metastasis

In a breakthrough in the understanding of how cancer spreads, researchers at the University of Virginia School of Medicine have identified a substance secreted by lung cancer cells that enables them to metastasize, beginning their deadly march to other sites in the body. [More]
Study explores cost-effectiveness of targeted treatment for cancer

Study explores cost-effectiveness of targeted treatment for cancer

Health economics helps insurers, health care systems and providers make treatment decisions based on the cost of extra "units" of health arising from a specific treatment. [More]
Multiplexed testing for EGFR and ALK gene rearrangements may be cost-effective for NSCLC treatment

Multiplexed testing for EGFR and ALK gene rearrangements may be cost-effective for NSCLC treatment

Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker-guided treatment is cost-effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States. [More]

EGFR–TKI response worse in NSCLC patients with rare EGFR mutations

In patients with non-small-cell lung cancer, rare epidermal growth factor receptor mutations are associated with a poorer response to EGFR–tyrosine kinase inhibitors compared with frequently occurring ones, according to a study published in Lung Cancer. [More]

Chemotherapy plus radiation improves survival in R1 NSCLC patients

US researchers have identified a survival benefit of postoperative combination chemotherapy and radiation treatment in patients with non-small-cell lung cancer who have microscopically positive surgical margins, regardless of pathological stage. [More]
Alectinib active against leptomeningeal metastases in ALK-positive NSCLC

Alectinib active against leptomeningeal metastases in ALK-positive NSCLC

Patients with anaplastic lymphoma kinase-rearranged non-small-cell lung cancer who have leptomeningeal metastases may benefit from treatment with the second-generation ALK inhibitor alectinib, a case series suggests. [More]
VATS lobectomy best for NSCLC patient short-term outcomes

VATS lobectomy best for NSCLC patient short-term outcomes

Video-assisted thoracoscopic surgery lobectomy offers better short-term outcomes for patients with early-stage non-small-cell lung cancer than open lobectomy, multi-institutional research confirms. [More]
Advertisement